- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07223021
En studie av Fludarabin-dosering hos barn og unge voksne med B-celle akutt lymfatisk leukemi
Forbedring av hendelsesfri overlevelse ved optimalisering av fludarabin-eksponering under lymfodepletering for CAR T-celleterapi: en randomisert, multikenterstudie med barn og unge voksne med B-celle akutt lymfatisk leukemi (INFLUENCE)
The researchers are doing this study to find out whether PK-targeted fludarabine is an effective Lymphodepletion (LD) chemotherapy approach for people with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) who will receive tisagenlecleucel CAR T-cell therapy. The researchers will compare PK-targeted fludarabine dosing with standard fludarabine dosing to see which treatment approach is more effective. The researchers will also look at whether PK-targeted fludarabine dosing is feasible (practical), the side effects of the study treatment, and how the study treatment affects people's quality of life. The researchers will measure quality of life by having participants complete questionnaires.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
- Navn: Kevin Curran, MD
- Telefonnummer: 1-833-MSK-KIDS
- E-post: currank@mskcc.org
Studer Kontakt Backup
- Navn: Jaap Jan Boelens, MD, PhD
- Telefonnummer: 1-833-MSK-KIDS
Studiesteder
-
-
New York
-
New York, New York, Forente stater, 10065
- Rekruttering
- Memorial Sloan Kettering Cancer Center
-
Hovedetterforsker:
- Kevin Curran, MD
-
Ta kontakt med:
- Kevin Curran, MD
- Telefonnummer: 1-833-MSK-KIDS
-
Ta kontakt med:
- Jaap Jan Boelens, MD,PhD
- Telefonnummer: 1-833-MSK-KIDS
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45229
- Rekruttering
- Cincinnati Children's Hospital Medical Center
-
Ta kontakt med:
- Christine Phillips, MD
- Telefonnummer: 513-636-4266
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104
- Rekruttering
- Children's Hospital of Philadelphia
-
Ta kontakt med:
- Regina Myers, MD
- Telefonnummer: 267-426-0762
-
-
Tennessee
-
Memphis, Tennessee, Forente stater, 38105
- Har ikke rekruttert ennå
- St. Jude Children's Research Hospital
-
Ta kontakt med:
- Aimee Talleur, MD
- Telefonnummer: 901-595-4215
-
-
Texas
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- Texas Children's Hospital
-
Ta kontakt med:
- Rayne Rouce, M.D., B.S.
- Telefonnummer: 832-822-4242
-
-
-
-
-
Utrecht, Nederland
- Rekruttering
- Prinses Máxima Centrum
-
Ta kontakt med:
- Friso Calkoen, MD
- Telefonnummer: +31 88 972 7272
-
-
-
-
-
Münster, Tyskland
- Rekruttering
- University Children's Hospital Münster
-
Ta kontakt med:
- Claudia Rossig, MD
- Telefonnummer: +49 17641091917
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Patients with B-ALL and eligible to receive commercial tisagenlecleucel.
-
Patient's weight > 9 kg at time of lymphodepleting chemotherapy
-
Adequate organ function at time of LD is required and is defined:
- Hepatic: Serum bilirubin ≤ 2 mg/dL, unless benign congenital hyperbilirubinemia
- Hepatic: AST and ALT < 5x the upper limit of normal for age, unless thought to be leukemic disease-related
- Renal: Calculated glomerular filtration rate (GFR) ≥ 70 ml/min/1.73m^2. (based on Schwartz formula GFR (mL/min/1.73 m²) = (36.2 × Height in cm) / Creatinine in mg/dL
- Cardiac: LVEF ≥ 50% by multi-gated acquisition scan (MUGA), resting echocardiogram, or cardiac magnetic resonance imaging (MRI) within 6 weeks of screening
- Pulmonary: Oxygen saturation as recorded by pulse oximetry of ≥ 90% on room air
-
Adequate performance status:
- Age ≥ 16 years: ECOG ≤ 1 or Karnofsky > 60% at treatment
- Age < 16 years: Lansky ≥ 60% at treatment
-
Willing to participate as research subject and provide written informed consent from parents/legal representative, patient, and age-appropriate assent as appropriate before any study specific screening procedures are conducted, according to local, regional or national law and legislation.
Exclusion Criteria:
- Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to the study drugs, or drugs chemically related to study treatment or excipients that contraindicate their participation, including fludarabine, cyclophosphamide and tisagenlecleucel.
- Patients with tisagenlecleucel that is deemed out of specification (OOS) will be excluded from this protocol
- Clinically significant active and uncontrolled infection confirmed by clinical evidence, imaging, or positive laboratory tests (e.g., blood cultures, PCR for DNA/RNA etc.)
- Patient/parent/guardian unable to give informed consent or unable to comply with the treatment protocol.
- Pregnant or lactating women
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Standard Fludarabine regimen followed by CAR-T
Fludarabine 30 mg/m2/dose x 4 doses on days -6 to -3 (or -7 to -4) |
Fludarabine 30 mg/m2/dose x 4 doses on days -6 to -3 (or -7 to -4) All patients will receive Cyclophosphamide 500 mg/m2 IV on days -6 and -5 (or -7 and -6). Targeted fludarabine LD: Fludarabine 40 mg/m2/dose x 2 doses on days -6 and -5 (or -7 and -6), with doses on days -4 and -3 (or -5 and -4, if starting lymphodepletion on day -7) adjusted based on PK analysis to target a cumulative area under the curve (AUC) of 18 mg*h/L (range 17.5-18.5mg*h/L) will be infused based on institutional guidelines. |
|
Eksperimentell: Targeted fludarabine regimen followed by CAR-T
Fludarabine 40 mg/m2/dose x 2 doses on days -6 and -5 (or -7 and -6), with doses on days -4 and -3 (or -5 and -4, if starting lymphodepletion on day -7) adjusted based on PK analysis to target a cumulative area under the curve (AUC) of 18 mg*h/L (range 17.5-18.5mg*h/L |
Fludarabine 30 mg/m2/dose x 4 doses on days -6 to -3 (or -7 to -4) All patients will receive Cyclophosphamide 500 mg/m2 IV on days -6 and -5 (or -7 and -6). Targeted fludarabine LD: Fludarabine 40 mg/m2/dose x 2 doses on days -6 and -5 (or -7 and -6), with doses on days -4 and -3 (or -5 and -4, if starting lymphodepletion on day -7) adjusted based on PK analysis to target a cumulative area under the curve (AUC) of 18 mg*h/L (range 17.5-18.5mg*h/L) will be infused based on institutional guidelines. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
compare the event free survival (EFS )
Tidsramme: 28 days
|
EFS is defined as time from randomization until non-response at day 28 after CAR T cell infusion, loss of B-cell aplasia <6 months from the time of CAR T cell infusion, disease relapse, initiation of anti-leukemic therapy or death of any cause |
28 days
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
overlevelse
Tidsramme: 2 år
|
2 år
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Kevin Curran, MD, Memorial Sloan Kettering Cancer Center
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Neoplasmer
- Sykdommer i immunsystemet
- Infeksjoner
- Virussykdommer
- Neoplasmer etter histologisk type
- DNA-virusinfeksjoner
- Lymfesykdommer
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Lymfom, Non-Hodgkin
- Lymfom, B-celle
- Lymfom
- Epstein-Barr-virusinfeksjoner
- Herpesviridae-infeksjoner
- Tumorvirusinfeksjoner
- Hemic og lymfatiske sykdommer
- Burkitt lymfom
- Organiske kjemikalier
- Hydrokarboner
- Fosforamid -sennep
- Nitrogen sennepsforbindelser
- Sennepsforbindelser
- Hydrokarboner, halogenert
- Fosforamider
- Organofosforforbindelser
- Cyklofosfamid
- fludarabin
Andre studie-ID-numre
- 25-072
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .